Exact Sciences nets more than $200 million from secondary stock sale

Exact Sciences Corp. said it netted about $238 million from a secondary stock sale after expenses were deducted.

The Madison company, maker of the Cologuard DNA stool test for colorectal cancer, sold 7 million additional shares of common stock at $35 each, for gross proceeds of $245 million. The sale closed on Monday. ...